The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Letter To The Editor

Expanding the Horizons Of Proton Beam Therapy

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
BYLINEDOWNLOAD PDFTABLE OF CONTENTS

The Cancer Letter recently published information regarding proton therapy facilities in the U.S., highlighting a contention that 85 percent of patients treated with protons have prostate cancer, the logical implication of which would be that this important resource is utilized minimally for other cancers. In this response, we wish to correct this erroneous impression and also wish to highlight the direction that this technology is moving in.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Byline
Minesh P. Mehta
Professor of radiation oncology, University of Maryland School of Medicine; Medical director, Maryland Proton Treatment Center
Katja Langen
Associate professor of radiation oncology, University of Maryland School of Medicine;
Associate chief of proton physics, Maryland Proton Treatment Center
William F. Regine
Isadore and Fannie Schneider Foxman Chair and Professor of Radiation Oncology, University of Maryland School of Medicine; Executive director, Maryland Proton Treatment Center
Table of Contents

YOU MAY BE INTERESTED IN

Black History MonthPodcast

Black History Month: Otis Brawley shares how lessons learned in West Side Detroit shape his stance on cancer prevention
“Trying to realize how good we actually could be if our system were truly efficient is what Otis is all about”

Growing up in inner-city Detroit, Otis Brawley had a thriving community made up of his parents, Jesuit priests, friends, and neighbors encouraging him that he could do anything he put his mind to. 
By Robert A. Winn, Otis W. Brawley and Preston Willett
Capitol Hill

After a brief government shutdown, FY26 funding bill is signed into law
NIH gets $415M raise, NCI gets $128M more, CDMRP funding largely restored

On Feb. 3, the House of Representatives passed the Senate Amendment to H.R. 7148, the Consolidated Appropriations Act, 2026, by a vote of 217 to 214. Later that day, President Donald Trump signed the bill into law, officially ending the brief partial government shutdown that began on Jan. 31. 
By Jacquelyn Cobb
Byline
Minesh P. Mehta
Professor of radiation oncology, University of Maryland School of Medicine; Medical director, Maryland Proton Treatment Center
Katja Langen
Associate professor of radiation oncology, University of Maryland School of Medicine;
Associate chief of proton physics, Maryland Proton Treatment Center
William F. Regine
Isadore and Fannie Schneider Foxman Chair and Professor of Radiation Oncology, University of Maryland School of Medicine; Executive director, Maryland Proton Treatment Center
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account